🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

518 results for “Cho” Clear

  1. CRD-4730, Encapsulation of microcrystalline cellulose into HPMC capsules to match the CRD-4730 active capsules in appearance

    Lacuna Pharma Pty Ltd

    Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

    phase 2 small molecule active

    1 trial

  2. Cadonilimab

    Second Affiliated Hospital of Soochow University

    Immunotherapy

    phase 2 small molecule active

    1 trial

  3. Chidamide Tablets； PD-L1 Inhibitor (as per chosen drug's prescribing information)；Carboplatin； Etoposide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  4. Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer A phase Ib/II, open-label, modular, dose-finding and dose-expansion study to explore safety, tolerability, pharmacokinetics, and anti-tumor activity of novel therapeutics in patients with early relapsed metastatic triple-negative breast cancer

    The George Institute

    Patients with hormone-receptor negative and HER2-negative (IHC 0, 1+ or IHC 2+/ISH-) breast cancer with early relapse while on (neo) adjuvant systemic treatment or within 12 months from the end of all treatments with curative intent.

    phase 2 other active

    1 trial

  5. Cholecalciferol

    Hospital Authority, Hong Kong

    Hematologic Neoplasms

    phase 2 small molecule active

    1 trial

  6. DCCR (diazoxide choline) extended-release tablets

    SOLENO THERAPEUTICS INC

    SH2B1 Deficiency Obesity

    phase 2 small molecule active

    1 trial

  7. DNS-6288, DNS-6288

    Lacuna Pharma Pty Ltd

    Catecholaminergic Polymorphic Ventricular Tachycardia

    phase 2 small molecule active

    1 trial

  8. Durvalumab

    Syndax Pharmaceuticals

    Unresectable Intrahepatic Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  9. E7090

    Eisai Co.,

    Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  10. EDP-305 1 mg

    ENANTA PHARMACEUTICALS INC

    Primary Biliary Cholangitis

    phase 2 small molecule completed

    1 trial

  11. EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)

    ABEONA THERAPEUTICS INC.

    Onychomycosis

    phase 2 small molecule completed

    1 trial

  12. Engineered Mitochondrial Vaccine (IMP3-Mito)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  13. Enteric coated sevelamer

    Sanofi Pasteur

    Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  14. Entinostat

    Syndax Pharmaceuticals

    Metastatic Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  15. Evinacumab

    Regeneron UK Limited

    Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  16. Gemcitabine

    Chongqing Precision Biotech Co., Ltd

    Pancreatic Cancer, Adult

    phase 2 small molecule terminated

    1 trial

  17. Golexanolone Placebo Capsules, oral capsules, soft, GR3027 10 mg

    COGNITION THERAPEUTICS INC

    Primary biliary cholangitis (PBC)

    phase 2 small molecule active

    1 trial

  18. INBRX-109

    Inhibrx Biosciences

    Conventional Chondrosarcoma

    phase 2 small molecule active

    1 trial

  19. ISIS 301012

    IONIS PHARMACEUTICALS INC

    Hypercholesterolemia, Familial

    phase 2 small molecule completed

    1 trial

  20. ISIS 301012 or Placebo

    IONIS PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 2 small molecule completed

    2 trials

  21. ISIS 301012 or Placebo

    IONIS PHARMACEUTICALS INC

    Hypercholesterolemia, Familial

    phase 2 small molecule completed

    1 trial

  22. Iloperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Parkinson Disease Psychosis

    phase 2 small molecule terminated

    1 trial

  23. Infigratinib

    BridgeBio Oncology Therapeutics

    Hypochondroplasia

    phase 2 small molecule active

    1 trial

  24. Infigratinib

    BridgeBio Oncology Therapeutics

    Achondroplasia

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources